Current Headlines

  1. GSK, AstraZeneca And Labcyte Form Alliance To Develop Acoustic Mass Spectrometry - A Novel Sample Handling Technology For MS-Based Drug Discovery

    Labcyte Inc. recently announced that GSK has joined its consortium with AstraZeneca to combine acoustic liquid dispensing technology from Labcyte with Mass Spectrometry (MS) for use in high throughput small molecule screening and other drug discovery applications.

  2. New Drug Discovery Collaboration Targets Novel Treatments Against Diseases

    Southern Research and the University of TennesseeHealth Science Center (UTHSC) have formed a partnership to advance promising research that could lead to new drugs that address unmet medical needs.

  3. Q BioMed Announces Development Partnership With Sphaera Pharma

    Q BioMed Inc. (OTCQB: QBIO), a biotechnology acceleration company, announced today a partnership with Sphaera Pharma to develop a new and proprietary analog of QBM-001 for pediatric developmental nonverbal disorder

  4. Merck To Advance Bispecific Antibody Drug Candidate Developed Using Zymeworks’ Azymetric Platform Into Preclinical Development

    Zymeworks Inc. (“Zymeworks”), a clinical-stage biopharmaceutical company dedicated to the discovery, development and commercialization of next-generation bispecific and multifunctional biotherapeutics, recently announced that Merck (known as MSD outside the US and Canada) has provided formal notification of their plans to advance a bispecific drug candidate into preclinical development

  5. Incysus Submits Investigational New Drug (IND) Application For Allogeneic Gamma-Delta T Cell Immunotherapy For Leukemia And Lymphoma

    Incysus, Ltd., a biopharmaceutical company focused on delivering an innovative gamma-delta (γδ) T cell immunotherapy for the treatment of cancers, today announced the submission of an IND application with the U.S. Food and Drug Administration (FDA) to initiate a Phase 1 study of expanded and activated allogeneic γδ T cells for patients with blood cancers following haploidentical stem cell transplantation

  6. Catalent To Acquire Cook Pharmica For $950M

    Catalent, Inc., the leading global provider of advanced delivery technologies and development solutions for drugs, biologics, and consumer health products, recently announced it has reached an agreement to acquire Bloomington, Indiana-based Cook Pharmica LLC, an integrated provider of drug substance and drug product manufacturing and related services.

  7. Mitobridge Adds NAD+ Modulation As A Therapeutic Approach For Improving Mitochondrial Function

    Mitobridge, Inc., a biopharmaceutical company pioneering the discovery and development of products that improve mitochondrial function, broadens its therapeutic approach to include Nicotinamide Adenine Dinucleotide (NAD+) pathway modulation

  8. Karus Therapeutics Announces First Cancer Patients Dosed With KA2507, A Small Molecule HDAC6-Selective Inhibitor, In A Phase I Clinical Trial

    Karus Therapeutics Ltd (‘Karus’), a leader in the design and development of innovative medicines with breakthrough potential in the treatment of cancer, recently announced that the first patients have been dosed with its histone deacetylase 6 (HDAC6) inhibitor, KA2507, in a Phase I clinical study

  9. DelMar Pharmaceuticals Receives IND Allowance From FDA To Initiate Clinical Trials Of VAL-083 For The Treatment Of Ovarian Cancer

    DelMar Pharmaceuticals, Inc. (Nasdaq: DMPI) ("DelMar" and "the Company"), a biopharmaceutical company focused on the development of new cancer therapies, today announced that the U.S. Food and Drug Administration ("FDA") has allowed an additional Investigational New Drug Application ("IND") to study its lead drug candidate VAL-083 as a potential treatment for ovarian cancer

  10. New indication For BRIVIACT® (Brivaracetam): UCB's Newest Antiepileptic Drug Approved By FDA As Monotherapy Treatment Of Partial-Onset Seizures In Adults

    UCB announced today that the U.S. Food and Drug Administration (FDA) has approved a supplemental new drug application (sNDA) for BRIVIACT® (brivaracetam) CV as monotherapy for partial-onset (focal) seizures (POS) in patients 16 years and older with epilepsy